Novel anti-inflammatory peptide alleviates liver ischemia-reperfusion injury.

Xiangdong Li,M. Hou,Huiquan Wang,Zhipeng Xu,Lin Chen,Ruiyan Xiong,Xuejun Xu,Kaineng Sun,Minjun Ji,Hao Chang,Yuxiao Zhu,Lu Chen,Jon Rob Padde,Chunxiang Shen,Liyong Pu,Yangyue Ni
DOI: https://doi.org/10.7555/JBR.38.20240020
2024-05-25
Journal of Biomedical Research
Abstract:Ischemia-reperfusion injury (IRI) remains inevitable in liver surgeries, macrophages play a critical role in the development of IRI, but little is known about the macrophages regulate pathogenesis of IRI. Based on target-guided screening, we identified a small 3 kDa peptide (SjDX5-271) from various schistosome egg-derived peptides that induced M2 macrophage polarization. SjDX5-271 treatment protected the mice against liver IRI through promoting M2 macrophage polarization, the protective effect was abrogated when the macrophages were depleted. Transcriptomic sequencing showed that the TLR signaling pathway was significantly inhibited in macrophages derived from the SjDX5-271 treatment group. We further identified that SjDX5-271 promotes M2 macrophage polarization by inhibiting the TLR4/MyD88/NF-κB signaling pathway and further alleviates hepatic inflammation in liver IRI. Collectively, SjDX5-271 exhibits promising therapeutic effects in IRI and represents a novel therapeutic approach for IRI, even in immune-related diseases. This study revealed the development of a new biologic from the parasite and enhanced our understanding of host-parasite interplay, providing a blueprint for future therapies for immune-related diseases.
Biology,Medicine
What problem does this paper attempt to address?